JP4949230B2 - 細胞調製方法および装置 - Google Patents
細胞調製方法および装置 Download PDFInfo
- Publication number
- JP4949230B2 JP4949230B2 JP2007505991A JP2007505991A JP4949230B2 JP 4949230 B2 JP4949230 B2 JP 4949230B2 JP 2007505991 A JP2007505991 A JP 2007505991A JP 2007505991 A JP2007505991 A JP 2007505991A JP 4949230 B2 JP4949230 B2 JP 4949230B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- body fluid
- cells
- mononuclear cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 210000004027 cell Anatomy 0.000 claims description 165
- 210000005087 mononuclear cell Anatomy 0.000 claims description 108
- 210000001124 body fluid Anatomy 0.000 claims description 106
- 239000010839 body fluid Substances 0.000 claims description 99
- 210000003714 granulocyte Anatomy 0.000 claims description 90
- 210000003743 erythrocyte Anatomy 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 79
- 239000003463 adsorbent Substances 0.000 claims description 70
- 238000000926 separation method Methods 0.000 claims description 66
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 29
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 29
- 229920002301 cellulose acetate Polymers 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 16
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 14
- 238000004891 communication Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 30
- 239000000463 material Substances 0.000 description 27
- 238000005119 centrifugation Methods 0.000 description 26
- 229920000642 polymer Polymers 0.000 description 25
- 210000005259 peripheral blood Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 239000011886 peripheral blood Substances 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 210000001185 bone marrow Anatomy 0.000 description 14
- -1 polyethylene Polymers 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 239000011118 polyvinyl acetate Substances 0.000 description 5
- 229920002689 polyvinyl acetate Polymers 0.000 description 5
- 238000007127 saponification reaction Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229920001059 synthetic polymer Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000012670 alkaline solution Substances 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 239000012798 spherical particle Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000028922 artery disease Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 240000000047 Gossypium barbadense Species 0.000 description 1
- 235000009429 Gossypium barbadense Nutrition 0.000 description 1
- 101000578940 Homo sapiens PDZ domain-containing protein MAGIX Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102100028326 PDZ domain-containing protein MAGIX Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000012345 acetylating agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950009865 nafamostat Drugs 0.000 description 1
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- External Artificial Organs (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
前記体液を顆粒球吸着材と接触させる工程Aと、
工程Aによる処理中または処理後の試料の、単核球と赤血球とを分離することができる条件下での遠心分離、工程Aによる処理中または処理後の試料への、単核球と赤血球とを分離することができる細胞分離剤の添加、および工程Aによる処理中または処理後の試料の、単核球と赤血球とを分離することができる細胞分離膜による分離からなる群から選択される少なくとも1種の処理を行う工程Bとを含む、単核球を含む細胞画分の調製法、あるいは
前記体液の、単核球と赤血球とを分離することができる条件下での遠心分離、前記体液への、単核球と赤血球とを分離することができる細胞分離剤の添加、および前記体液の、単核球と赤血球とを分離することができる細胞分離膜による分離からなる群から選択される少なくとも1種の処理を行う工程Cと、
工程Cによる処理後の試料を顆粒球吸着材と接触させる工程Dとを含む、単核球を含む細胞画分の調製法。
工程Aと工程B、あるいは工程Cと工程Dとが同一容器内で行われる、(1)記載の方法。
顆粒球吸着材を収容してなる第1手段と、
前記体液または(1)に定義される工程Aによる処理中または処理後の試料を遠心分離する手段、単核球と赤血球とを分離することができる細胞分離剤を収容してなる手段、および単核球と赤血球とを分離することができる細胞分離膜を備えた手段からなる群から選択される第2手段とを備える、前記装置。
顆粒球吸着材と、単核球と赤血球とを分離することができる細胞分離剤とを収容してなる手段を備える、前記装置。
顆粒球吸着材を収容してなる遠心分離用容器と、該容器を遠心する手段とを備える、前記装置。
F:滴定に使用した0.1規定水酸化ナトリウム水溶液のファクター
温和なアルカリ性条件は、当業者が過度の実験なくして達成できる。
前記体液を顆粒球吸着材と接触させる工程Aと、
工程Aによる処理中または処理後の試料の、単核球と赤血球とを分離することができる条件下での遠心分離、工程Aによる処理中または処理後の試料への、単核球と赤血球とを分離することができる細胞分離剤の添加、および工程Aによる処理中または処理後の試料の、単核球と赤血球とを分離することができる細胞分離膜による分離からなる群から選択される少なくとも1種の処理を行う工程Bとを含む、単核球を含む細胞画分の調製法に関する。
前記体液の、単核球と赤血球とを分離することができる条件下での遠心分離、前記体液への、単核球と赤血球とを分離することができる細胞分離剤の添加、および前記体液の、単核球と赤血球とを分離することができる細胞分離膜による分離からなる群から選択される少なくとも1種の処理を行う工程Cと、
工程Cによる処理後の試料を顆粒球吸着材と接触させる工程Dとを含む、単核球を含む細胞画分の調製法に関する。
哺乳動物体液としてヒト末梢血、細胞分離材としてHES、顆粒球吸着材として部分鹸化酢酸セルロースビーズを用いて以下の操作を行った。
酢酸セルロースをジメチルスルホキシドとプロピレングリコールの混合溶剤に溶解し、この溶液を特開昭63−117039に記載された方法(振動法)により液滴化し、凝固させて酢酸セルロースの球形の粒子を得た。得られた球形粒子の粒径は、約300μmであった。この粒子を沈降体積比で、0.1規定水酸化ナトリウム水溶液と1:1(V/V)の割合で混合し、30分間接触させることにより、部分加水分解反応を行った。吸着体沈降体積の約200倍量の蒸留水にて洗浄後、生理食塩水液(最終濃度で5IU/mlのヘパリンを含む)にて置換を行い、部分鹸化酢酸セルロースビーズを得た。このときの部分鹸化酢酸セルロースビーズの鹸化度は、47.5%(置換率は52.5%)であった。
健常人ボランティアから末梢血を採取した。このものは、1mlあたり赤血球を4.3×109個、白血球を4.6×106個(そのうち単核球が2.1×106個、顆粒球が約2.3×106個)が含まれるものであった。
(1)で調製した沈降体積1mlの部分鹸化酢酸セルロースビーズに(2)で調製した末梢血を2ml加え、37℃、1時間、20rpmで撹拌しながらインキュベートした。この操作を吸着材処理とした。吸着材処理後、細胞分離剤として400μl(全量に対してHES濃度が1%となる量)のHES40(NIPRO社製、6%HES含有0.9%食塩液)を加え、50gで5分間遠心して、上清を回収し、これを処理区1とした。また、吸着材処理後、1500μl(全量に対してHES濃度が2.57%となる量)のHES40を加え、50gで5分間遠心して、上清を回収し、これを処理区2とした。さらに、吸着材処理後、RPMI1640培養液(Gibco)を2ml加え、800μl(全量に対してHES濃度が1%となる量)のHES40を加え、50gで5分間遠心して、上清を回収し、これを処理区3とした。
対照区2〜4においては、赤血球除去率は全て98%以上と優れていたが、顆粒球除去率は最も高い対照区2で64%に留まり、対照区3,4では30%程度であった。
哺乳動物体液としてブタ骨髄液、細胞分離剤としてHES、顆粒球吸着材として部分鹸化酢酸セルロースビーズを用いて以下の操作を行った。
酢酸セルロースをジメチルスルホキシドとプロピレングリコールの混合溶剤に溶解し、この溶液を特開昭63−117039に記載された方法(振動法)により液滴化し、凝固させて酢酸セルロースの球形の粒子を得た。得られた球形粒子の粒径は、約300μmであった。この粒子を沈降体積比で、0.1規定水酸化ナトリウム水溶液と1:1(V/V)の割合で混合し、30分間接触させることにより、部分加水分解反応を行った。吸着体沈降体積の約200倍量の蒸留水にて洗浄後、生理食塩水液(最終濃度で5IU/mlのヘパリンを含む)にて置換を行い、部分鹸化酢酸セルロースビーズを得た。このときの部分鹸化酢酸セルロースビーズの鹸化度は、47.5%(置換率は52.5%)であった。
ミニブタ(クラウン、30kg)の腸骨より骨髄液を採取した。このものは、1mlあたり赤血球が5.0×109個、白血球が1.0×107個(そのうち単核球画分細胞が3.0×106個、顆粒球が5.0×106個)含まれるものであった。
(1)で調製した沈降体積1mlの部分鹸化酢酸セルロースビーズに(2)で調製したブタ骨髄液を2ml加え、37℃、1時間、20rpmで撹拌しながらインキュベートした。この操作を吸着材処理とした。吸着材処理後、400ul(全量に対してHES濃度が1%となる量)のHES40(NIPRO社製、6%ヒドロキシエチルデンプン加0.9%食塩液)を加え、50gで5分間遠心して、上清を回収し、これを処理区4とした。また、吸着材処理後、1500ul(全量に対してHES濃度が2.57%となる量)のHES40を加え、50gで5分間遠心して、上清を回収し、これを処理区5とした。さらに、吸着材処理後、RIMI1640培養液(Gibco)を2ml加え、800ul(全量に対してHES濃度が1%となる量)のHES40を加え、50gで5分間遠心して、上清を回収し、これを処理区6とした。
対照区6〜8では、赤血球は除去できるものの、顆粒球画分除去は3〜20%程度であったのに対し、処理区4〜6では赤血球、顆粒球共に80%以上であり、処理区5、6では顆粒球画分除去率が90%以上であった。
Claims (6)
- 単核球、顆粒球および赤血球を含有する哺乳動物の体液からの、単核球を含む細胞画分の調製法であって、
前記体液をアセチル基によって置換されている水酸基の割合が全水酸基の35〜53%である酢酸セルロースである顆粒球吸着材と接触させる工程Aと、
工程Aによる処理中または処理後の試料への、単核球と赤血球とを分離することができるHES(ヒドロキシエチル澱粉)である細胞分離剤の添加を行う工程Bとを含む、単核球を含む細胞画分の調製法、あるいは
前記体液への、単核球と赤血球とを分離することができるHES(ヒドロキシエチル澱粉)である細胞分離剤の添加を行う工程Cと、
工程Cによる処理後の試料をアセチル基によって置換されている水酸基の割合が全水酸基の35〜53%である酢酸セルロースである顆粒球吸着材と接触させる工程Dとを含む、単核球を含む細胞画分の調製法。 - 工程Aまたは工程Dが、顆粒球吸着材が充填されたカラムに前記体液または工程Cによる処理後の試料を通過させるか、顆粒球吸着材と前記体液または工程Cによる処理後の試料とを同一容器内で接触させることにより行われる請求項1記載の方法。
- 工程Aと工程B、あるいは工程Cと工程Dとが同一容器内で行われる、請求項1記載の方法。
- 単核球、顆粒球および赤血球を含有する哺乳動物の体液から、単核球を含む細胞画分を調製するための装置であって、
アセチル基によって置換されている水酸基の割合が全水酸基の35〜53%である酢酸セルロースである顆粒球吸着材を収容してなる第1手段と、
単核球と赤血球とを分離することができるHES(ヒドロキシエチル澱粉)である細胞分離剤を収容してなる第2手段とを備える、前記装置。 - 第1手段と第2手段とが液体連通している、請求項4記載の装置。
- 単核球、顆粒球および赤血球を含有する哺乳動物の体液から、単核球を含む細胞画分を調製するための装置であって、
アセチル基によって置換されている水酸基の割合が全水酸基の35〜53%である酢酸セルロースである顆粒球吸着材と、単核球と赤血球とを分離することができるHES(ヒドロキシエチル澱粉)である細胞分離剤とを収容してなる手段を備える、前記装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007505991A JP4949230B2 (ja) | 2005-03-03 | 2006-03-01 | 細胞調製方法および装置 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005058748 | 2005-03-03 | ||
JP2005058748 | 2005-03-03 | ||
PCT/JP2006/303907 WO2006093205A1 (ja) | 2005-03-03 | 2006-03-01 | 細胞調製方法および装置 |
JP2007505991A JP4949230B2 (ja) | 2005-03-03 | 2006-03-01 | 細胞調製方法および装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2006093205A1 JPWO2006093205A1 (ja) | 2008-08-07 |
JP4949230B2 true JP4949230B2 (ja) | 2012-06-06 |
Family
ID=36941234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007505991A Expired - Fee Related JP4949230B2 (ja) | 2005-03-03 | 2006-03-01 | 細胞調製方法および装置 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4949230B2 (ja) |
WO (1) | WO2006093205A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031006A1 (en) * | 2008-09-12 | 2010-03-18 | Cryopraxis Criobiologia Ltda. | Ischemic tissue cell therapy |
EP2698422B1 (en) * | 2011-04-11 | 2016-06-22 | Kaneka Corporation | Mononuclear cell preparation material and mononuclear cell preparation method using same |
WO2013161679A1 (ja) | 2012-04-27 | 2013-10-31 | 株式会社カネカ | 有核細胞捕捉フィルターまたはこれを利用した有核細胞調製法 |
CN112899153A (zh) * | 2021-04-21 | 2021-06-04 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种白血病细胞分离提取装置 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01275601A (ja) * | 1988-04-27 | 1989-11-06 | Kanegafuchi Chem Ind Co Ltd | セルロース系粒子 |
JPH0587808A (ja) * | 1991-09-30 | 1993-04-06 | Sekisui Chem Co Ltd | 顆粒球吸着用担体の製造方法 |
JP2002171965A (ja) * | 2000-12-04 | 2002-06-18 | Kansai Tlo Kk | 骨髄単核球細胞の分離、濃縮方法及び血管再生剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5446812A (en) * | 1977-09-21 | 1979-04-13 | Asahi Chem Ind Co Ltd | Separation of granulocyte |
US5573678A (en) * | 1987-01-30 | 1996-11-12 | Baxter International Inc. | Blood processing systems and methods for collecting mono nuclear cells |
JP2501500B2 (ja) * | 1991-09-30 | 1996-05-29 | 積水化学工業株式会社 | 顆粒球吸着用担体及び顆粒球除去装置 |
JP2004121144A (ja) * | 2002-10-04 | 2004-04-22 | Asahi Medical Co Ltd | 単核球の採取方法 |
-
2006
- 2006-03-01 JP JP2007505991A patent/JP4949230B2/ja not_active Expired - Fee Related
- 2006-03-01 WO PCT/JP2006/303907 patent/WO2006093205A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01275601A (ja) * | 1988-04-27 | 1989-11-06 | Kanegafuchi Chem Ind Co Ltd | セルロース系粒子 |
JPH0587808A (ja) * | 1991-09-30 | 1993-04-06 | Sekisui Chem Co Ltd | 顆粒球吸着用担体の製造方法 |
JP2002171965A (ja) * | 2000-12-04 | 2002-06-18 | Kansai Tlo Kk | 骨髄単核球細胞の分離、濃縮方法及び血管再生剤 |
Also Published As
Publication number | Publication date |
---|---|
WO2006093205A1 (ja) | 2006-09-08 |
JPWO2006093205A1 (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4925829B2 (ja) | 顆粒球吸着材 | |
JP6016867B2 (ja) | 血液または骨髄中の一定細胞集団をその他のものを枯渇させることにより精製するための方法 | |
ES2690970T3 (es) | Sorbente polimérico para eliminación de impurezas de sangre total y productos de sangre | |
MX2007011218A (es) | Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa. | |
JP6528399B2 (ja) | 細胞濃縮液の製造方法 | |
JP5975985B2 (ja) | 単核球調製材、及び前記調製材を利用した単核球調製方法 | |
JP4949230B2 (ja) | 細胞調製方法および装置 | |
JP2012210187A (ja) | 細胞懸濁液の濃縮方法 | |
JP2015012837A (ja) | 細胞濃縮液の製造方法 | |
JP6814632B2 (ja) | 顆粒球除去方法 | |
JP4958554B2 (ja) | リンパ球増殖抑制因子の吸着材及び処理方法 | |
CN113016780A (zh) | Vx702用于制备血小板体外保存剂的应用及相关血小板 | |
WO2016150566A1 (en) | System and method for providing isolated concentrated multipotent stromal cells for administration | |
JP4583325B2 (ja) | 吸着材の処理方法 | |
JP4043094B2 (ja) | 細胞分離器 | |
JP4640991B2 (ja) | 単球選択捕捉材料 | |
Suaudeau et al. | The Ito “Flow‐Through” Centrifuge A New Device for Long‐Term (24 hours) Plasmapheresis without Platelet Deterioration | |
JPS62290469A (ja) | 膜型血漿分離器 | |
WO2023046874A1 (en) | Immune cell treatment | |
JPWO2006106763A1 (ja) | リンパ球増殖抑制因子の除去方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120214 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120307 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4949230 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |